The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study

Moreland, 2002, Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion, Arthritis Rheum, 46, 1470, 10.1002/art.10294 Schiff, 2011, Abatacept treatment for rheumatoid arthritis, Rheumatology (Oxford), 50, 437, 10.1093/rheumatology/keq287 Orencia (250mg powder for concentrate for solution for infusion) Summary of Product Characteristics. Available from URL: http://www.medicines.org.uk/emc/medicine/19714/SPC/ [Accessed 10 Sep 2015]. Product monograph: Orencia (abatacept). Available from URL: http://www.bmscanada.ca/static/products/en/pm_pdf/ORENCIA_EN_PM.pdf [Accessed 10 Sep 2015]. Stavropoulos-Kalinoglou, 2011, Obesity in rheumatoid arthritis, Rheumatology (Oxford), 50, 450, 10.1093/rheumatology/keq266 Naranjo, 2008, Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study, Arthritis Res Ther, 10, R30, 10.1186/ar2383 Labitigan, 2014, Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis, Arthritis Care Res (Hoboken), 66, 600, 10.1002/acr.22185 Ljung, 2015, Obesity and the risk for development of rheumatoid arthritis – results from a population-based nested case-control study, Arthritis Rheumatol, 67, 1989 Liu, 2015, Impact of obesity on the disease course of rheumatoid arthritis, Arthritis Rheumatol, 67, 59 Shin, 2015, The clinical impact of overweight in rheumatoid arthritis patients: comparison between Korea and other countries within the Comora study, Arthritis Rheumatol, 67, 1926 Gremese, 2013, Obesity and reduction of the response rate to anti-tumor necrosis factor alpha in rheumatoid arthritis: an approach to a personalized medicine, Arthritis Care Res (Hoboken), 65, 94, 10.1002/acr.21768 Ottaviani, 2015, Body mass index and response to infliximab in rheumatoid arthritis, Clin Exp Rheumatol, 33, 478 Sandberg, 2014, Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis, Ann Rheum Dis, 73, 2029, 10.1136/annrheumdis-2013-205094 Iannone, 2015, Obesity reduces the drug survival of second line biological drugs following a first TNF-alpha inhibitor in rheumatoid arthritis patients, Joint Bone Spine, 82, 187, 10.1016/j.jbspin.2014.12.006 D’Agostino, 2015, In patients with rheumatoid arthritis and an inadequate response to methotrexate, does body mass index influence the efficacy of abatacept on inflammation when measured by power doppler ultrasonography? Results from the APPRAISE study, Ann Rheum Dis, 74, 231 Nüßlein, 2016, Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study, Clin Exp Rheumatol, 34, 489 Iannone, 2014, Body mass does not affect clinical outcomes of therapy with abatacept in rheumatoid arthritis (RA) patients. A pan-European analysis of RA registries, Ann Rheum Dis, 73, 498, 10.1136/annrheumdis-2014-eular.5630 Murthy, 2011, Pharmacokinetics of subcutaneous abatacept support a fixed dosing regimen in adult patients with rheumatoid arthritis, Ann Rheum Dis, 70, 460 Nüßlein, 2014, Does body mass index impact long-term retention with abatacept in patients with RA who have received at least one prior biologic agent? 2-year results from a real-world, international, prospective study, Ann Rheum Dis, 66, 1088 Nüßlein, 2014, Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study, BMC Musculoskelet Disord, 15, 14, 10.1186/1471-2474-15-14 Arnett, 1988, The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis, Arthritis Rheumatol, 31, 315, 10.1002/art.1780310302 Burmester, 2014, Ann Rheum Dis, 73, 69, 10.1136/annrheumdis-2013-203523 Kivitz, 2014, Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, Arthritis Care Res (Hoboken), 66, 1653, 10.1002/acr.22384 Pers, 2015, Response to tocilizumab in rheumatoid arthritis is not influenced by the body mass index of the patient, J Rheumatol, 42, 580, 10.3899/jrheum.140673 Gardette, 2016, Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study, Clin Rheumatol, 35, 857, 10.1007/s10067-016-3183-3 Corbo, 2009, Subcutaneous administration of abatacept in patients with rheumatoid arthritis: pharmacokinetics, safety and immunogenicity, Ann Rheum Dis, 68, S574 Dandona, 2004, Inflammation: the link between insulin resistance, obesity and diabetes, Trends Immunol, 25, 4, 10.1016/j.it.2003.10.013 Stavropoulos-Kalinoglou, 2012, Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis, Arthritis Res Ther, 14, R160, 10.1186/ar3900 Ursini, 2015, Abatacept improves whole-body insulin sensitivity in rheumatoid arthritis: an observational study, Medicine (Baltimore), 94, e888, 10.1097/MD.0000000000000888